Recent research indicates that two Alzheimer's medications, lecanemab (Leqembi) and donanemab (Kisunla), can significantly prolong the duration of time patients can live independently. A study published in the Alzheimer's Association journal, conducted by Washington University School of Medicine in St. Louis, examined the impact of these drugs on 282 early-stage Alzheimer's patients.

Both medications target amyloid beta plaques, a hallmark of Alzheimer's, with the aim of slowing cognitive decline. The study found that lecanemab extended independent living by approximately 10 months, while donanemab added about 8 months. For patients with mild symptoms, the average independent living time was estimated to be 29 months without treatment, 39 months with lecanemab, and 37 months with donanemab.

Senior author Dr. Sarah Hartz highlighted the significance of these findings, stating that extending independent living for approximately a year could be substantial given the costs and implications associated with losing independence. She emphasized that the study's objective was to provide context for patients and families making treatment decisions, not to endorse or discourage the use of these medications.

Dr. Christopher Weber, of the Alzheimer's Association (not involved in the study), noted the clinical relevance of these findings, particularly for early-stage patients. He underscored the importance of early intervention to maximize benefits, as later-stage treatment yielded less pronounced results. Dr. Weber also emphasized the need for ongoing research and investment in Alzheimer's to improve understanding, early detection, and effective treatments.

However, it's crucial to acknowledge the potential risks associated with these medications. Dr. Chris Vercammen, a geriatrics and palliative care specialist, cautioned that lecanemab and donanemab do not cure or reverse Alzheimer's, and their benefits are limited to early-stage patients. He stressed the importance of thorough discussions with doctors to weigh the potential benefits against significant risks, including brain swelling, bleeding, and substantial financial costs.

Dr. Hartz acknowledged the study's limitations, noting that the participants were highly engaged in Alzheimer's research and typically well-educated, raising questions about the generalizability of the findings. She recommended that individuals considering these treatments consult their doctors to evaluate the potential risks and benefits in their specific situations. Eisai, the manufacturer of Leqembi, highlighted the recent FDA approval of a less frequent dosing schedule, potentially easing the burden on patients and caregivers.